Your browser doesn't support javascript.
Severe coronavirus disease 2019 (COVID-19) pneumonia patients treated successfully with a combination of lopinavir/ritonavir plus favipiravir: Case series.
Koba, Hayato; Yoneda, Taro; Kaneda, Tomoya; Ueda, Tsukasa; Kimura, Hideharu; Kasahara, Kazuo.
  • Koba H; Respiratory Medicine Komatsu Municipal Hospital Komatsu city Japan.
  • Yoneda T; Cellular Transplantation Biology Kanazawa University Graduate School of Medical Science Kanazawa city Japan.
  • Kaneda T; Respiratory Medicine Komatsu Municipal Hospital Komatsu city Japan.
  • Ueda T; Cellular Transplantation Biology Kanazawa University Graduate School of Medical Science Kanazawa city Japan.
  • Kimura H; Cardiovascular medicine Komatsu Municipal Hospital Komatsu city Japan.
  • Kasahara K; Respiratory Medicine Komatsu Municipal Hospital Komatsu city Japan.
Clin Case Rep ; 8(12): 3143-3148, 2020 Dec.
Article in English | MEDLINE | ID: covidwho-797223
ABSTRACT
The combination therapy of Lopinavir/Ritonavir plus Favipiravir might be a treatment option for patients with COVID-19. Serum ferritin levels and lymphocytopenia are promising markers for disease severity and disease progression that are commonly available in general clinical practice.
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Type of study: Case report / Prognostic study Language: English Journal: Clin Case Rep Year: 2020 Document Type: Article

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Type of study: Case report / Prognostic study Language: English Journal: Clin Case Rep Year: 2020 Document Type: Article